Utility of placental growth factor for prediction of 30-day adverse event in emergency department population with non-ST elevation acute coronary syndrome

Clinical Laboratory

Volumn 56, Issue 5-6, 2010, Pages 215-222

  Marković, Mirjana ^a   Ignjatović, Svetlana ^b   Dajak, Marijana ^b   Majkić Singh, Nada ^b  

^a University School of Pharmacy   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

30 day outcome; Non ST elevation acute coronary syndrome; Placental growth factor

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE MB; NATRIURETIC PEPTIDE RECEPTOR B; PLACENTAL GROWTH FACTOR; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK FACTOR; ST SEGMENT ELEVATION; THORAX PAIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAUSE OF DEATH; CREATINE KINASE, MB FORM; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY PROTEINS; SURVIVORS; TROPONIN T;

EID: 77953303733     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006; 48: 1-11. (Pubitemid 44202476)
2. Mitchell AM, Brown MD, Menown IBA, Kline JA. Novel protein markers of acute coronary syndrome complications in low-risk outpatients: a systematic review of potential use in the emergency department. Clin Chem 2005; 51: 2005-12.
3. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-62.
4. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-38.
5. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810-24. (Pubitemid 40577917)
6. Iwama H, Uemura S, Naya N, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 2006; 47: 1559-67.
7. Apple FS, Smith SW, Pearce LA, Murakami MM. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2009; 55: 93-100.
8. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-40.
9. Heeschen C, Dimmeler S, Fichtlscherer S, et al, for the CAPTURE Investigators. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004; 291: 435-41.
10. Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 307-11.
11. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007; 53: 874-81. (Pubitemid 46744243)
12. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007; 53: 552-74.
13. Thomas L, Huber AR. Renal function-estimation of glomerular filtration rate. Clin Chem Lab Med. 2006; 44: 1295-302. (Pubitemid 44706706)
14. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. New Eng J Med 2006; 354: 2473-83. (Pubitemid 43855050)
15. Dajak M, Marković M, Ignjatović S, Majkić-Singh N. Evaluation of quantikine ELISA test for the measurement of placental growth factor. Jugoslov Med Biohem 2006; 25(4): 488.
16. Sypniewska G, Sawicki M, Krintus M, Kozinski M, Kubica J. The use biochip cardiac array techology for early diagnosis of acute coronary syndromes. Journal of Medical Biochemistry 2009; 28: 293-9.
17. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-74.
18. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Atheroscler Thromb Vasc Biol 2007; 27: 15-26. (Pubitemid 46360377)
19. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part I: Introduction and cytokines. Circulation 2006; 113: 72-5.
20. Athanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 1998; 19: 465-73.
21. Cao Y, Ji WR, Qi P, Rosin A, Cao Y. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun 1997; 235: 493-8. (Pubitemid 27326507)
22. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993; 9: 259-68. (Pubitemid 24034347)
23. Failla CM, Odorisio T, Cianfarani F, Schietroma C, Puddu P, Zambruno G.. Placenta growth factor is induced in human keratinocytes during wound healing. J Invest Dermatol 2000; 115: 388-95.
24. Tordjman R, Delaire S, Plouet J, et al. Erythroblasts are a source of angiogenic factors. Blood 2001; 97: 1968-74.
25. Bottomley MJ, Webb NJ, Watson CJ, et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol 2000; 119: 182-8.
26. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel target for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-70.
27. Eli K. Preventing pathological regression of blood vessels. J Clin Invest 2003; 112(1): 27-9.
28. Wu AHB. Markers for early detection of cardiac diseases. Scand J Clin Lab Investig 2005; 65(240): 112-21.
29. Marković M, Ignjatović S, Majkić-Singh N, Dajak M. Placental growth factor in acute coronary syndrome patients with non ST-elevation. Labmedicine 2009; 11: 675-8.
30. Cassidy A, Chiuve SE, Manson JE, et al. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009; 29: 134-9.
31. Hennekens CH. Risk factors for coronary heart disease in women. Cardiol Clin 1998; 16(1): 1-8.
32. Milner KA, Funk M, Arnold A, Vaccarino V. Typical symptoms are predictive of acute coronary syndromes in women: results. Am Heart J 2002; 143(2): 283-8.
33. Canto JG, Goldberg RJ, Hand MM, Bonow RO, Sopko G, Pepine CJ, et al. Symptom presentation of women with acute coronary syndromes: myth vs reality. Arch Intern Med 2007; 167(22): 2405-13.